文献速递银屑病与炎症性皮肤病

古塞奇尤单抗治疗面部和/或生殖器银屑病:GULLIVER研究第12周中期分析

Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-06-26

GULLIVER是一项为期52周的意大利观察性研究,评估古塞奇尤单抗在真实世界中治疗面部和/或生殖器中重度银屑病(sPGA≥3)的疗效与安全性。第12周中期分析纳入351例患者,83.3%的面部银屑病患者和76.5%的生殖器银屑病患者达到主要终点(sPGA 0/1)。古塞奇尤单抗在这两个难治部位显示出有效性和安全性,可能是一个有价值的治疗选择。

要点

  • 面部银屑病患者第12周sPGA 0/1应答率为83.3%。
  • 生殖器银屑病患者第12周sPGA 0/1应答率为76.5%。
  • 基线PASI>10患者平均PASI从19.0降至2.2,安全性良好。

核心结论

  • 古塞奇尤单抗治疗面部和生殖器银屑病有效且安全,可能成为这些难治部位的有效治疗选择。

研究设计与样本

  • GULLIVER是一项为期52周的意大利观察性研究,评估古塞奇尤单抗在真实世界中的有效性及安全性。
  • 纳入成人面部和/或生殖器中重度银屑病患者(sPGA评分≥3),共351例。

主要发现

  • 83.3%的面部银屑病患者和76.5%的生殖器银屑病患者在第12周达到面部或生殖器sPGA评分0(清除)或1(几乎清除)。
  • 在基线各sPGA成分评分≥3的患者中,面部或生殖器sPGA成分的应答率相似。
  • 基线PASI评分>10的患者,平均PASI评分从19.0(SD 8.3)改善至2.2(SD 4.8)。
  • 未观察到严重不良事件(SAE)。

关键数值与推荐

  • 主要终点为第12周达到面部或生殖器sPGA评分0或1的患者百分比。
  • 评估基线各sPGA成分评分≥3患者的面部或生殖器sPGA成分评分变化。
  • 评估基线PASI评分高于或低于10的患者PASI评分变化。

临床怎么用

  • 对于面部和/或生殖器中重度银屑病患者,古塞奇尤单抗可作为考虑的治疗选项。
  • 治疗12周时应评估面部和生殖器部位的sPGA应答。

局限性

  • 本文为中期分析结果,仅报告第12周数据。
  • 研究为观察性设计,非随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Facial (FP) and genital psoriasis (GP) significantly affect patients' quality of life. Despite the advances in treatments, limited data on efficacy and safety are available on these difficult-to-treat areas. Guselkumab is an interleukin (IL)-23 inhibitor which has been proven effective in treating patients with moderate-to-severe plaque psoriasis. OBJECTIVES: The aim of this interim analysis was to report the efficacy and safety of guselkumab in the treatment of patients with FP and/or GP. MATERIALS AND METHODS: GULLIVER is a 52-week Italian observational study to evaluate the effectiveness and safety of guselkumab in a real-life setting in patients with FP and/or GP. Adult patients with facial and/or genital moderate-to-severe psoriasis (sPGA score ≥ 3) were included. The primary endpoint of this analysis was the percentage of patients achieving a facial or genital sPGA score of 0 (clear) or 1 (almost clear), at Week 12. The change in the score of the facial or genital sPGA components in patients with a score ≥3 for each sPGA component was assessed. PASI score in patients with a baseline PASI above or below 10 was evaluated. RESULTS: Overall, 351 patients were included in the study; 83.3% of FP and 76.5% of GP patients achieved the primary endpoint. Similar response rates were observed for the facial or genital sPGA components in patients with a baseline facial or genital sPGA score ≥3 in each component. Among patients with a baseline PASI score >10, mean PASI score improved from 19.0 (SD 8.3) to 2.2 (SD 4.8). Forty-four AEs were observed in 32 patients; two mild and transient AEs (fatigue and nausea) were considered treatment related. No SAEs were observed. CONCLUSIONS: Guselkumab, showing to be effective and safe in treating FP and GP, may be a valid therapeutic option for patients with psoriasis localized in these difficult-to-treat areas.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bonifati C, Lembo S, Richetta AG, et al. Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study. J Eur Acad Dermatol Venereol. 2024. PMID: 38924150. doi:10.1111/jdv.20187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。